From unpatched cars to hijacked clouds, this week's Threatsday headlines remind us of one thing — no corner of technology is ...
Details of the Phase 3 MASCOT trial investigating amlenetug for the treatment of patients with Multiple System Atrophy (MSA) will be presented at the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback